Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aggressive medical treatment-Beijing Tiantan Hospital
- Development stage
- Unknown
- Lead developer
- Beijing Tiantan Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
aggressive medical treatment-Beijing Tiantan Hospital refers to a specific therapeutic regimen utilized in the DREAM-PRIDE clinical trial (NCT04152707) for the prevention of recurrent stroke in patients with symptomatic intracranial atherosclerotic disease (ICAD). Developed by Beijing Tiantan Hospital, this aggressive protocol is characterized by an intensified dual antiplatelet therapy (DAPT) duration and rigorous risk factor management. The pharmacological component involves the daily administration of aspirin (100 mg) combined with either clopidogrel (75 mg) or ticagrelor (90 mg twice daily) for a period of six months, which is double the duration of standard medical treatment. Additionally, the regimen incorporates comprehensive management of vascular risk factors, including hypertension, diabetes, and dyslipidemia, alongside behavioral interventions such as smoking cessation and structured exercise programs.
- Other names
- Aggressive medical treatmentAMTAggressive medical treatment (DREAM-PRIDE)
02
Targets
P2Y12 (Purinergic P2Y12 receptor)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aggressive medical treatment-Beijing Tiantan Hospital.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aggressive medical treatment-Beijing Tiantan Hospital.